News & Trending Insurance News

Medicare's New $50 Weight-Loss Drug Benefit Starts July 1 - Here's Who Qualifies

A new Medicare program could slash GLP-1 drug costs.

wegovy weight loss medication
Updated June 24, 2026
Fact check checkmark icon Fact checked
Google Logo Add Us On Google info

For more than two decades, Medicare has been legally barred from covering medication used solely for weight loss. That long-standing rule is now shifting, at least temporarily, with a new program that could significantly lower the cost of popular GLP-1 drugs.

The Medicare GLP-1 Bridge program is set to run from July 1, 2026, through December 31, 2027. During that window, certain Medicare beneficiaries are going to be able to access select weight-loss and diabetes-related medications for a flat $50 monthly copayment, a dramatic reduction that could help them keep more cash in their pocket

Get instant access to hundreds of discounts

Over 50? Join AARP today— because if you’re not a member you could be missing out on huge perks like discounts on travel, dining, and even prescriptions.

Get 25% off membership — just $15 for your first year with auto-renewal — and a free gift if you join today.

Become an AARP member now

What the Bridge program covers

The program applies to Medicare Part D enrollees, including those with standalone drug plans and those enrolled in Medicare Advantage plans that include prescription drug coverage.

Eligible participants have access to a limited group of GLP-1 medications, including Wegovy (both injection and tablet forms), Zepbound (KwikPen), and Foundayo.

These medications are part of a class of drugs that help regulate blood sugar, slow digestion, and reduce appetite, which is why they have become widely used for both diabetes management and weight loss.

Who qualifies for the program

Eligibility is structured into three tiers, based primarily on body mass index (BMI) and related health conditions. This tiered system determines who qualifies for the program.

Tier 1 includes adults with a BMI of 35 or greater. No additional medical condition is required at this level, making it the most straightforward path to qualification.

Tier 2 applies to adults with a BMI of 30 or greater who also have at least one qualifying condition. These conditions include issues such as uncontrolled high blood pressure, chronic kidney disease, or heart failure.

Tier 3 expands eligibility further to adults with a BMI of 27 or greater, but only if they also have more serious health indicators. These could include prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.

Across all tiers, enrollment in a Medicare Part D plan or a Medicare Advantage plan with drug coverage is required. Without that prescription coverage, beneficiaries are not eligible to participate in the Bridge program.

How to access the benefit

Unlike standard prescription coverage, the GLP-1 Bridge program has a more centralized approval process.

Patients cannot simply take a prescription to the pharmacy and pay the $50 copay. Instead, prior authorization is required, and the process must be initiated by a health care provider.

Doctors must submit the request through a centralized system managed by the Centers for Medicare & Medicaid Services (CMS), rather than through a patient's regular Part D plan. This additional step is designed to ensure that only eligible patients receive access based on the program's criteria. Once approved, patients could begin accessing the medication at the fixed monthly cost.

Resolve $10,000 or more of your debt

National Debt Relief could help you resolve your credit card debt with an affordable plan that works for you. Just tell them your situation, then find out your debt relief options.1

Sign up for a free debt assessment here

The $50 copay explained

The flat $50 monthly copayment is one of the most attention-grabbing features of the program, but it comes with important limitations.

Most notably, the $50 payment does not count toward a beneficiary's Part D deductible. It also does not apply to the annual out-of-pocket spending cap that many Medicare enrollees rely on to limit total drug costs.

That means the lower monthly price does not reduce other prescription-related expenses within a Medicare plan.

Key fine print to know

Several additional details could affect how useful the program is for different households.

One of the most important involves the low-income subsidy program, often called Extra Help. Beneficiaries who qualify for Extra Help typically receive assistance with prescription drug costs under Part D. However, that assistance cannot be applied to medications obtained through the GLP-1 Bridge program.

This means some lower-income beneficiaries may not see additional savings beyond the $50 monthly cost, even if they would normally pay less for other prescriptions.

Timing is another important factor. Because the program is temporary, running only through the end of 2027, access is not guaranteed long-term. Patients who begin treatment under the program may need to reassess their options once it expires.

Medicare is changing how it covers weight-loss drugs

The introduction of the Bridge program marks a notable change in how Medicare approaches weight-loss medications.

Historically, coverage has been limited to treatments tied directly to specific medical conditions, such as diabetes. Drugs prescribed primarily for weight loss have largely been excluded, even as obesity-related health issues have become more prominent.

By opening limited access to GLP-1 medications, the program signals a growing recognition of the role these treatments play in preventing more serious and costly health conditions.

What this means for your health care costs

For eligible beneficiaries, the program could offer meaningful savings. Many GLP-1 drugs have been out of reach for Medicare recipients due to high out-of-pocket costs. A fixed $50 monthly price makes these medications far more accessible, at least in the short term.

However, the structure of the program means it does not reduce overall Medicare drug spending in the same way traditional coverage does. And because it is temporary, it may not provide a long-term solution for those who rely on these medications.

Beneficiaries who think they may qualify should start by speaking with their health care provider. Patients could also visit the Medicare.gov/glp1bridge page or call 1-800-MEDICARE for more information about the program and how to get started.

Bottom line

The Medicare GLP-1 Bridge program represents a major, if temporary, shift in coverage for weight-loss medications. Eligible beneficiaries could access drugs like Wegovy and Zepbound for just $50 per month, which could keep more cash in your wallet by dramatically reducing out-of-pocket medication costs.

However, the program comes with important restrictions and a limited timeline, so understanding the fine print is key to making the most of the benefit.

Up To 5% Cash Back

  • $0 annual fee
  • Intro APR on purchases and balance transfers
  • Apply Now
  • INTRO OFFER: Unlimited Cashback Match for all new cardmembers. Discover will automatically match all the cash back you’ve earned at the end of your first year! There’s no minimum spending or maximum rewards. You could turn $150 cash back into $300.
  • Earn 5% cash back on everyday purchases at different places you shop each quarter like grocery stores, restaurants, gas stations, and more, up to the quarterly maximum when you activate. Plus, earn unlimited 1% cash back on all other purchases.
  • Redeem cash back for any amount. No annual fee.
  • Get a 0% intro APR for 15 months on purchases and balance transfers. Then 17.49% to 26.49% Standard Variable Purchase APR applies, based on credit worthiness.
  • Terms and conditions apply.
Discover <span class='whitespace-nowrap'>it<sup>®</sup></span> Cash Back
4.7
info

on Issuer's secure website

Read Card Review

Intro Offer

Discover will match all the cash back you’ve earned at the end of your first year.

Annual Fee

$0

+

Why we like it


Financebuzz logo

Thanks for subscribing!

Please check your email to confirm your subscription.